Articles tagged with Chimeric Antigen Receptors
Researchers have developed CAR T cell-based microrobots that can autonomously navigate to tumor sites and exert immune effects. The M-CAR T demonstrated controllable movement and penetrated artificial tumor tissues under magnetic-acoustic sequential actuation.
A new study found that antibiotic treatment and certain types of microorganisms in the gut can impact CAR T-cell therapy outcomes. Patients with higher levels of Bifidobacterium longum had improved overall survival rates, while those with other bacteria were associated with poorer responses.
Researchers at Universitätsklinikum Erlangen have successfully treated a patient with anti-synthetase syndrome using CAR T-cells. The innovative treatment approach has shown promising results, allowing the patient to recover entirely from their autoimmune disease after six months.
Researchers at the University of Texas M. D. Anderson Cancer Center have identified CD70 as a novel therapeutic target for eliminating drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer. CD70 targeting strategies showed significant anti-tumor activity, eliminating resistant cells in laboratory models.
Researchers at Harvard's Wyss Institute developed a method to fine-tune CAR-T cell stimulation using artificial antigen-presenting scaffolds. This approach enhances consistency and potency of resulting CAR-T cell products, allowing for better cancer treatment outcomes.
Researchers at Karolinska Institutet have developed a new type of CAR T-cell therapy that effectively attacks and destroys ovarian cancer cells, significantly prolonging the lives of mice with the disease. The treatment has shown promising results in reducing tumor size and curing several mice.
Scientists at St. Jude Children's Research Hospital developed a new design for chimeric antigen receptors (CARs) by adding a molecular anchor, increasing the anti-cancer activity of cellular immunotherapies in cancer models. The anchored CARs improved cancer killing and survival rates in animal models of multiple tumor types.
A new method utilizes an unnatural sugar to anchor cytokines to T cells, enhancing their functions without systemic side-effects. The approach has shown promise in stimulating the host immune system against tumor cells and inhibiting tumor growth in mice with melanoma.
Researchers at UCSF have developed a novel approach to prevent antibodies from triggering immune rejection of engineered therapeutic and transplant cells. By using a decoy receptor, they can capture the antibodies and take them out of circulation before they can kill the therapeutic cells.
Researchers at UCSF and IBM Research create a predictive model that encodes commands for cells to kill cancer cells. By combining words that guide engineered immune cells, they can predict which elements should be included in a cell to carry out precise behaviors. This advance allows scientists to rapidly design new cellular therapies.
USCF researchers have developed a new approach called CAR Pooling to compare different re-engineered T cells with varying molecular features. The screen revealed new and surprising receptors that make these therapeutic cells more powerful, promising a better treatment for blood cancers.
Researchers have found therapies that can help patients with relapsed multiple myeloma who tried CAR-T therapy, including bispecific antibodies and other types of CAR-T cell therapy. The study analyzed 79 patients and found that stem cell transplants and other drug combinations showed some efficacy in these patients.
Researchers at Universidad de Navarra identified a biomarker that predicts CAR T cell therapeutic capacity, which could improve treatment outcomes for patients. The study found that high CAR density in CAR T cells is associated with a worse clinical response in hematological tumors.
A new CAR NK cell engineering approach requires two signals to eliminate target cells, improving tumor specificity and enhancing anti-tumor activity. This strategy mitigates NK cell exhaustion and fratricide, leading to better focus on and attack of only the tumor cells.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
A study led by University of Pennsylvania scientists reveals how tumor-derived factors stimulate trogocytosis, a process that can help cancer cells evade detection and grow unchecked. Blocking this process improved the effectiveness of CAR T cell therapy in mice.
A combination of immunotherapy and virotherapy using myxoma virus provides new hope for patients with treatment resistant cancers. The approach boosts the immune capacity to effectively target and destroy cancer cells, inducing a form of cell death called autosis.
A University of Houston engineer has developed technology to determine which patients are likely to respond to CAR T-cell therapy for lymphoma, saving time and increasing success rates. The TIMING method analyzes interactions between T cells and tumor cells, identifying a key ligand molecule that predicts patient response.
Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.
Researchers found that administering tisagenlecleucel at the higher end of the approved dose range significantly improves overall and event-free survival in young patients. The study suggests that using higher doses of CAR-T therapy can achieve more effective and long-term responses without increasing toxicity risk.
Researchers developed a method to produce generic CAR T cells from induced pluripotent stem cells (iPS cells), which could be produced at scale for multiple patients. The new cells showed enhanced anti-tumor activity and comparable efficacy to current clinical-grade cells.
A Purdue University chemical engineer has improved upon traditional methods to produce off-the-shelf human immune cells that show strong antitumor activity. The new method, developed by Xiaoping Bao, mass-produces CAR-neutrophils from human pluripotent stem cells with superior and specific antitumor activities against glioblastoma.
Researchers have developed a way to fine-tune CAR T cell therapy to strike a balance between safety and efficacy, reducing the risk of severe side-effects. The new approach enables customisation of potency levels for individual patients, broadening its potential as a first-line treatment.
A new PET imaging agent, 18F-AlF-FAPI-74, has been found to effectively monitor and predict treatment response of an up-and-coming cancer therapy. This non-invasive imaging approach can help inform clinical decision-making early in the course of treatment.
Scientists at Max Delbrück Center identify EBAG9 gene as key inhibitor of T cell function against tumors, releasing the brake and boosting immune response. The discovery aims to develop CAR T cells without EBAG9 for more effective leukemia treatments.
A new cell therapy has been developed to target and eliminate leukemia stem cells that cause disease relapse. The treatment uses genetically engineered T cells with a chimeric antigen receptor that recognizes specific markers on these cancer cells.
Researchers at USC have developed an innovative treatment for prostate cancer, known as synthetic immune receptor (SIR-T) therapy, which has shown promising results in preclinical studies. The new technology was adapted from CAR-T therapy and aims to revolutionize the treatment of not only prostate cancer but also other cancers.
Researchers identified OR2H1 as an effective target for CAR T cells in solid tumors, inhibiting growth in lung and ovarian cancer. The study suggests that targeting this protein could lead to the development of new CAR T therapies for a wide variety of patients with solid tumors.
Researchers at Massachusetts General Hospital have developed a novel CAR T-cell construct that targets acute myeloid leukemia (AML) effectively. The combination of drug therapy and engineering approaches enhanced the treatment's ability to adhere to tumor cells, overcoming previous difficulties with antigen targeting.
Researchers identified a signature of nonresponse to CAR T therapy in leukemia cells, characterized by DNA methylation and stem cell-like phenotypes. Decreased expression of genes involved in antigen presentation also hindered the immune response.
A new CAR T-cell product targeting CLDN6 showed acceptable safety and early signs of efficacy in a phase I/II clinical trial. The therapy combined with an mRNA vaccine expanded transferred CAR T cells and improved tumor cell killing.
City of Hope researchers present new developments in cell therapy for acute myeloid leukemia and non-small cell lung cancer. A novel smoking cessation program increases patient desire to quit with personalized counseling.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
Researchers at Penn Medicine have discovered a new approach to treat solid cancers using CDH17CAR T cells, which selectively target and eliminate gastrointestinal (GI) solid tumors like gastric, pancreatic, and colorectal cancers in preclinical models. Unlike other immunotherapies, CDH17CAR T cells do not show toxicity to healthy tissues.
The ZUMA-12 trial shows axi-cel achieved a high rate of complete response in patients with high-risk large B-cell lymphoma, with an estimated overall survival rate of 91% at 12 months.
A team led by Reshmi Parameswaran at University Hospitals Seidman Cancer Center has developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers, which triples the targeted antigens on cancer cells. The new BAFF CART product is effective in killing multiple B-cell cancers with minimal side effects.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
Researchers discovered that aberrant splicing of CD22 mRNA leads to decreased protein expression in pediatric B-lymphoblastic leukemia cells. This results in resistance to CD22-directed immunotherapies, making it challenging for oncologists to identify patients who may not respond to these treatments.
Researchers have developed SEAKER cells, which combine target-seeking power with the ability to locally generate potent anticancer drug for double effect. The cells use an enzyme to release active prodrug at tumor site, killing both cancer cells and those nearby that do not contain the marker.
A clinical trial will harness synthetic chimeric antigen receptor (CAR) T cells to deplete immune B cells and plasma cells producing donor-specific antibodies, aiming to achieve a compatible kidney match for patients with pre-existing antibodies. The NIH-funded study, led by Penn Medicine, intends to begin enrolling patients in 2022.
A novel approach may reduce the serious adverse effect of cytokine release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy. Supressing interferon gamma (IFNγ) appears to prevent activation of macrophages and other immune cells that drive the syndrome without impacting CAR T-cell efficacy.
Researchers at the University of Texas MD Anderson Cancer Center demonstrated axi-cel's efficacy in treating high-risk lymphoma patients with enhanced responses and prolonged survival benefits. The study showed improved outcomes for patients with indolent non-Hodgkin lymphoma, with an estimated 81% overall survival rate at 24 months.
A new study published in the New England Journal of Medicine found that using CAR T therapy as a second-line treatment provided better outcomes compared to standard care in patients with diffuse large B-cell lymphoma. The two-year follow-up data showed a median event-free survival of 8.3 months in the CAR T arm versus 2 months in the s...
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.
Researchers create a porous microneedle to deliver CAR T cells into solid tumors, improving anti-tumor effects. The strategy showed enhanced tumor infiltration and amplification of CAR T cells in melanoma models.
A researcher at MUSC's Hollings Cancer Center is developing 'living drugs' by precision-engineering CAR Tregs to treat autoimmune diseases. The CAR Tregs can delay or reduce damaging inflammation, offering a potential solution for conditions like Type 1 diabetes.
A therapeutic antibody has been shown to unblock and normalise blood vessels inside cancerous tumours, enabling the more effective delivery of targeted cancer treatments. The findings also suggest that inhibiting LRG1 protein production can enhance the effectiveness of immunotherapies, including checkpoint inhibitors and CAR T-cell the...
Researchers at Children's Hospital of Philadelphia have developed a novel therapy that targets proteins essential for tumor growth and survival. Using a multi-omics approach, they identified peptides unique to neuroblastoma tumors, which are then targeted by peptide-centric chimeric antigen receptors (PC-CARs).
Researchers at USC Viterbi School of Engineering have discovered a way to boost the effectiveness of CAR T-cell therapy for treating solid tumors, including breast and melanoma. By engineering CAR T-cells to produce an enzyme called adenosine deaminase, they break down an immune-suppressive microenvironment, allowing cancer-killing cel...
A new study from Penn Medicine demonstrates that RN7SL1, a naturally occurring RNA, can activate the body's own natural T cells to seek out cancer cells that have escaped recognition by CAR T cells. This approach may help improve efforts to treat solid tumors.
Researchers have developed heat-controllable CAR T cells that can target and destroy cancerous tumors, while preventing relapse. The cells are engineered to produce immunomodulators under photothermal control, increasing their effectiveness against solid tumors.
Researchers at the University of Pennsylvania School of Medicine have identified a new mechanism of resistance in advanced chronic lymphocytic leukemia (CLL) patients to CAR T cell therapy. They found that inhibiting the BET protein with the small molecule inhibitor JQ1 can reinvigorate exhausted T cells and increase their production.
Researchers at UC San Diego developed a cancer immunotherapy that pairs ultrasound with CAR T-cell therapy to destroy malignant tumors while sparing normal tissue. The therapy significantly slowed down tumor growth in mice and showed minimal on-target, off-tumor side effects.
Researchers at La Jolla Institute for Immunology report that T cells can be engineered to clear tumors without succumbing to T cell exhaustion. Altering CAR T cells to overexpress BATF boosts the 'effector' program, making T cells better against solid tumors.
Moffitt Cancer Center experts present phase 2 results from several clinical studies evaluating the efficacy of CAR T-cell therapy, ixazomib maintenance therapy, and immunotherapies for various types of cancer, including acute lymphoblastic leukemia, multiple myeloma, prostate cancer, and triple-negative breast cancer.
Researchers discovered a sub-set of CAR T-cells called 'stem cell memory T-cells' that play a key role in destroying cancer and maintaining immune surveillance. These cells are critical to the long-term success of CAR T-cell therapy, which could improve treatment outcomes for patients with high-risk relapse.
Researchers designed cpLOV2 using circular permutation to simplify optogenetic device design. The new photoswitch maintained structural integrity and function, providing more choices for optogenetic application developments. It was successfully used to gate ORAI1 Ca2+ channel and control cell activities in a mouse model.
Researchers have made a significant breakthrough in immunotherapy design, using specifically designed receptors to completely clear brain cancer tumors in preclinical models. The approach has shown promise and could pave the way for new treatments for people with glioblastoma, an aggressive form of brain cancer.
Researchers have developed a new generation of CAR T cells that safely target and kill solid tumors in mice with mesothelioma, ovarian cancer, and glioblastoma. The 'prime-and-kill' molecular circuits enable specific recognition of tumor antigens on healthy tissues, reducing the risk of side effects.